Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Mei, Matthew; Palmer, Joycelynne; Tsai, Nicole; Simpson, Jennifer; O'Hearn, James; Stein, Anthony S.; Forman, Stephen J.; Spielberger, Ricardo; Cai, Ji-Lian; Htut, Myo; Nakamura, Ryotaro; Malki, Monzr M. Al; Herrera, Alex F.; Wong, Jeffrey Y.C.; Nademanee, Auayporn

doi:10.1016/j.clml.2023.05.011

Clinical Lymphoma Myeloma and Leukemia

2023

DOI: 10.1016/j.clml.2023.05.011

|View full text |Cite

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Matthew Mei¹,

Joycelynne Palmer²,

Nicole Tsai³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Radioligand Therapy in Lymphoma

Almeida,

Delgado Bolton,

Heringer

et al. 2024

PET Clinics

View full text Add to dashboard Cite

Radioligand Therapy in Lymphoma

Almeida,

Delgado Bolton,

Heringer

et al. 2024

PET Clinics

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Cited by 1 publication

References 45 publications

Radioligand Therapy in Lymphoma

Radioligand Therapy in Lymphoma

Contact Info

Product

Resources

About